Experience

Pheast Therapeutics

• United States
• Biotechnology
• 1 - 100 Employee

• Chief Scientific Officer

  • Sep 2021 - Present

  Palo Alto, California, United States Pheast Therapeutics is targeting macrophage checkpoints to activate the immune system against cancer cells.



Gilead Sciences

• United States
• Biotechnology Research
• 700 & Above Employee

• Senior Research Scientist II

  • Jul 2020 - Jul 2021

  Foster City, California, United States Following the acquisition of Forty Seven Inc. by Gilead Sciences, I led the Biomarkers Science teams for Gilead’s clinical stage anti-CD47 and anti-SIRPA agents. In this role, I led research efforts to understand clinical responses to our drugs In oncology indications, and worked in a cross-functional capacity to help inform both clinical development and biological research for these agents across disease areas.



Forty Seven Inc.

• United States
• Biotechnology Research
• 1 - 100 Employee

• Director of Translational Research

  • Jun 2019 - Jul 2020

  Menlo Park At Forty Seven, I led research programs aimed at understanding clinical responses to our first in pathway anti-CD47 therapy, as well as non-clinical research into the mechanism of action and therapeutic synergies of both anti-CD47 and anti-SIRPA agents. In April 2020, Forty Seven Inc. was acquired by Gilead Sciences (https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/gilead-completes-acquisition-of-forty-seven-inc)



Ab Initio Biotherapeutics, Inc.

• United States
• Biotechnology

• Co Founder and Head of Research

  • Mar 2015 - May 2019

  280 Utah Avenue, Suite 250, South San Francisco, CA 94080 Ab Initio focused on using a proprietary directed evolution engineering technology to create the next generation of protein-based drugs. In July 2019, Ab Initio was acquired by Ligand Pharmaceuticals. https://www.ligand.com/news-events/press-releases/detail/389/



Stanford University School of Medicine

• Hospitals and Health Care
• 1 - 100 Employee

• Postdoctoral Fellow

  • Jun 2013 - Oct 2015

  265 Campus Drive, SIM1 Bldg G3165, Stanford, CA 94305 Postdoctoral training in the laboratory of Dr. Irving Weissman, a world-renowned researcher at the Stanford University School of Medicine’s Institute for Stem Cell Biology and Regenerative Medicine. Building upon my previous experience in genetics, cancer biology, and small RNA signaling, during my appointment in Dr. Weissman’s lab I applied the principles of forward genetics to identify and study genes involved in immune evasion by tumors. This work identified several novel immuno-oncology… Show more Postdoctoral training in the laboratory of Dr. Irving Weissman, a world-renowned researcher at the Stanford University School of Medicine’s Institute for Stem Cell Biology and Regenerative Medicine. Building upon my previous experience in genetics, cancer biology, and small RNA signaling, during my appointment in Dr. Weissman’s lab I applied the principles of forward genetics to identify and study genes involved in immune evasion by tumors. This work identified several novel immuno-oncology drug targets, as well as novel engineered protein drug candidates. Show less



Columbia University Irving Medical Center

• United States
• Hospitals and Health Care
• 700 & Above Employee

• Graduate Student Researcher

  • 2006 - 2012

  Research in small RNA signaling, cancer genetics



Ernest Gallo Clinic and Research Center

• Biotechnology
• 1 - 100 Employee

• Undergraduate Research Assistant

  • Jan 2003 - Apr 2006

  5858 Horton St, Emeryville, CA 94608